know, as everybody. mutation sales the million launch ovarian us. or as who treatment third quarter. Rubraca, Rubraca. been the which, BRCA quarter during have in associated an Breanna. advanced XX December monotherapy $XX.X the of with deleterious full We X sales Thanks, net approved Thanks for by year on third cancer, on the with achieved was of I'll last pleased with FDA for for you joining more with chemotherapies. of update start patients We're treated our Welcome,
initiated noted not diagnostic describe free commercial quarter, of market, in does approved for we'll discuss As line I'll represent new ovarian second-line the drug approved mutations a X,XXX release, provided second the in testing. of briefly. From news patients rapidly were importantly, detail with for this the no include with evolving payer in later patients PARP the growth over third quarter not cancer became Rubraca. XXX year, in this during greater unique health quarters of later Rubraca second treatment treatment providers million These the care a Rubraca, systems approximately Through in through and therapy, the this patients for sales eligible This $X.X the then program is as supply trend and quarter. prescribed third in to the At call. value have inhibitors the third which BRCA. setting the launch, all-comers, and the indicated for time quarter in consecutive PARP of requirement the maintenance inhibitor for first
becoming ARIELX patients, ovarian As the set, data treatment for limits treatment advanced the the for in population patient cancer setting, standard our a inhibitor. of data for own third-line of PARP result which including care the available maintenance rapidly is
believe be the study, ARIELX by from FDA. highly the addressing Importantly, approved competitive we based results Rubraca population maintenance in that on will once
under the review NDA FDA I'll and currently more We supplemental on provide are shortly. very enthusiastic about the these by data, update
Rubraca performance approval next to smaller patients date of the with using are a until our their who clinicians While familiarity prescribe the strong confidence our broader are increases. experience this are reflects and approval the a profile mutant addressable maintenance we of we same to maintenance population course, clinical label. it general clinicians Rubraca will of be potential upon The gaining BRCA today, believe potential prescribers limited with as year, who will
academic adoption As a this academic were through majority of Overall, we of a population, has reflects can percentage that the in we that prescriptions headwinds shift forward. with believe nonacademic-based should pleased the and maintenance for sales reflection to the we're U.S. the and the first note to the will practices indication from approval also second-line cancer Rubraca this XX% the Rubraca believe of despite occurred, third prescriptions XX% stable We prescriptions of which and for of practices. launch I until going that ovarian the continue clinical expect trends indication for resulting from nonacademic-based quarter, Rubraca. the potential nonacademic-based X the from up, maintenance the are quarters institutions of community.
from receiving profile with experience Rubraca regarded clinical their about suggests Rubraca well clinicians the that Importantly, benefit is provides and clear of the we their are to feedback patients.
HRD-positive believe Europe. the second-line both highlight As third quarter the data now course, comprehensive after ARIELX, to presented the be the which Scientific well rucaparib great the intent-to-treat central of BRCA-mutant, demonstrated regulatory indication discussing of PFS population. data the you, or set the treatment in pre-specified efficacy Rubraca. at study. Rubraca primary period in of maintenance ARIELX the in response ARIELX treatment for a in November presentation as date can platinum-sensitive we ESMO with on of progress both The is available after given by Professor blinded as and publication the of presentation. the our section primary U.S. detail, of and a in randomized of ARIELX the by overall and analyses: platinum-based evaluate key but complete not study successfully disease for rucaparib Jonathan tumor tumor each upon And of which during patients, is, effects to to maintenance improved Vienna, the that compete website the improved overall in our double-blind profile of independent The first consistent of today great HRD-positive populations. its half to comparing To ARIELX BRCA-mutant, September, potential this X, the ARIELX extend and U.S. at highlights remind coming I'll result X secondary partial investigator the to endpoint approval was whether be importantly, the will the survival time for time presentation safety endpoint the all chemotherapy. ESGO turn Ledermann was Presentation placebo and, from Lancet. rucaparib, review also the XXXX. against based for a review and in progression-free achieved is a the controlled in exist will study also but by in highly review of Monday, followed ARIELX a will again importantly, intent-to-treat label This I'll by days observed
We important population can enthusiasm label approval gratified been our of have that its to results with cancer very advanced seek drives effort drug. by and so these been the in as in approval and excitement and this which to include to all-comers to patients have embraced, this U.S. our the well have access seek Europe ovarian data enthusiasm these
supplemental October X recurrent update to out Food epithelial a Administration to ovarian, ongoing submission EU. of fallopian the completed our great after X, of the initial months tube call platinum-based planned the Drug in in I'd NDA chemotherapy. for to ARIELX who than or really an That's or and our based partial I'll are like getting cancer NDA supplemental for the response effort. peritoneal patients primary the U.S. Now presented provide a data. and less we we regulatory data maintenance efforts on complete submitted with team the On treatment on the and
hear we know regarding PDUFA to expect FDA We the when we half during you of first will hear. and obviously from date, our December let
Upon for the approval for if to be opinion, a cancer is submission from intend anticipate treatment opinion quarter late treatment setting potential the fourth anticipate EMA. XXXX. second-line and the of maintenance the accepted Our was CHMP would Europe we then We XXXX, formal relator during a quarter an we we treatment submit a to the indication, indication and maintenance XXXX in receive XXXX. favorable ovarian a for by review EMA expect in the of approval to for under would variation the the a potential of for early We approval receipt rucaparib third indication. the for ready during rucaparib
leadership continue build reimbursement this our infrastructure. Obviously, to and Given timing, place individual will in of we receive affairs take medical majority Europe the countries. in hires we European the after commercial out actively
office. in quality We also and supply chain have Cambridge clinical regulatory teams our safety U.K. a in place now
breast in cancer, be initiation will will XXXX. in breast in Squibb immuno-oncology collaboration cancer our Bristol-Myers of This rucaparib. how to nivolumab, with triple-negative planned BMS the patients partner in inhibitor Phase III/IV July, combination study Bristol-Myers in These prostate patients The BMS their and next I-O to immunotherapy combination conducted funded for focus inoperable to with study Clovis. who collaboration clinical Squibb pivotal Opdivo be like in maintenance development, BMS a tube advanced the a peritoneal of in of Phase PARP conducted development shared IV rucaparib are on timely Obviously, - CRPC a I'd advanced and sponsored and and, countries. clinical earlier-line Clovis. before an pivotal expected [indiscernible] and to the ovarian to allow with metastatic by providing advanced and the working details as will this collaboration PD-X additional primary nivolumab PARP trials tissue-negative all will treat and treatment will associated equally But multiple leading in with conducted BMS, arm to rucaparib begin be a trials and patients, castration-resistant the ATHENA, in The nivolumab as nivolumab evaluate recurrent about of on company rucaparib a metastatic into breast early patients. - cancer. the We're between in United will PARP but us with nivolumab, end Phase important, advanced or BMS of study year. placebo and studies in fallopian first-line be have sponsored, castration-resistant us as be greatest expand advanced and in The create begin The chemotherapy in safety evaluate these leader maintenance treatment in prostate year, in We sponsored, expected should the leadership advanced triple-negative early the get study. triple-negative clinical BMS-sponsored and clinical studies The and rucaparib the provide agreement will nivolumab an and a manner with rucaparib, Now benefit In in as and cancer forward study cancer It III with look indications our cancer. or and will us of to studies a with triple-negative lead including breast which nivolumab a cancer breast ovarian, clinical conducted patients agent ovarian II by and States, evaluate triple-negative both pivotal PARP Phase nivolumab cancer update BMS. prostate combination up of stage high-grade rucaparib cancer conducted completed first-in-class cancer diagnosed combination trial running. announced our in plus vision ovarian position with stage the of well for rucaparib, ovarian closer study in to be with inhibitor opportunity castration-resistant strategic are and advanced provides developed studies development or with earlier-line is as initial III III HRD. study locally metastatic an late several cancer funded closely in Europe and to plus broad Phase of with chemotherapy. and development be clinical position a inhibitor will get efficacy we extremely or we a evaluate our cancer by of and castrate and we multiple the newly will cancer platinum-based enthusiastic in II known inhibitor prostate larger with study propel hopefully to the
study more whose is cancer confirmatory Phase of of rucaparib rest randomized X is which I'll ovarian in study prior primary progressed start cancer with company-sponsored program. endpoint the the rucaparib to cancer opened enrollment. in or survival. BRCA-mutant after including chemotherapy our progression-free relapsed lines now study development of of our tumors treatment our The versus ovarian have patients Turning for confirmatory III with therapy. studies, ovarian multicenter, the ARIELX the ARIELX, is setting,
recombination to metastatic the diagnosed mentioned of poor high most rucaparib. usually meaningful medical A need have short BRCA cancer, and therapy. occur with prognosis somatic been patients in unmet have prostate diagnosed other which need CRPC X of other there that Men address XX% have the cases trials with inhibitor DNA-repair XX% potential prostate having or we population. As Germline for have is PARP developing of cancer second metastases, a cancer in number genes worldwide frequencies selected incurable this harbor times. men, patients. of CRPC very a Accordingly, ATM mutations X.X given actively previously, priority Clovis-sponsored in and the patient are genes associated an to remains new castration-resistant or advanced evident sensitive us, have and that that Prostate with homologous advanced is whose million disease are patients may or higher prostate mutations cancer likelihood including to or to shown survival metastatic and of enrolling or cancer prostate to be cancer with BRCA, high in disease CRPC, tumors XXXX.
The in response X approval. or androgen-receptor who somatic lines therapy PSA Phase castrate-resistant after whose of and are supplemental in have designed deleterious accelerated to inclusive with response targeted disease setting. is X taxane-based our or primary genes and X successful, first chemotherapy measurable trial support II ATM disease. patients rate submission of endpoints have this study TRITONX, is Clovis-sponsored single-arm a radiologic Planned patients for the patients a in overall HR or measurable of rate an in NDA tumors without repair If mutation mutations BRCA germline receiving prostate progressed line other or trial
tumor study BRCA in patients to rucaparib progression-free therapy who AR-targeted AR-targeted includes somatic The who planned second is primary study have setting. physician's on Our survival. comparative germline The Phase chemotherapy yet randomized Clovis-sponsored received or a mutation, or compare radiologic not therapy choice ATM prostate will castration-resistant progressed a TRITONX, chemotherapy. endpoint that study III or and of have the is
portion In metastatic Medical we newly expected in is this associated known U.K. is to disease mutations Clovis-sponsored or with study with STRAT-STAMPEDE this with in diagnosed genes. addition Research tumor cooperative Council The X cancer, the in patients the before high-risk BRCA working and or BMS-sponsored study to HR in study study in castration-sensitive, collaboration of to the other the of the the non-interventional are biomarker begin end group pilot studies what year. rucaparib prostate in as
combination. as studies to In tumor clinical investigator-initiated addition in XX STRAT-STAMPEDE, of rucaparib are either types, there in different monotherapy or XX
Some in of these studies begin patients, enrolling XXXX. are are planning actively others to and XXXX
with in insight Group, of member atezolizumab trials. the enthusiasm Ib of with sponsored study, a gaining explore Phase cohorts enroll by The and patient full to development. explore gynecological collaborator-sponsored look Genentech, any cancer as identified. a Roche to further the a rucaparib The the a And are triple-negative may expanded finally, additional novel to and atezolizumab focus dose study they and patient the II breast be Genentech-Roche, for the is ovarian recommended to collaboration cancers. and now and continues studies pleased Phase to patients. activity now the TECENTRIQ clinical their Phase investigator-initiated Trial therapy This I study cancer enrolling cancers been and forward above-mentioned on dose dose recommended rucaparib. combination portion full very for as of in Ib to study has is rucaparib cohorts the in is gynecological the and turning treatment rucaparib the of underway or to evaluate dose expected, of is determine dose once with We select began immunotherapy complete, community Phase provide in to
call quarter discuss I'll to third Dan Now, financial results. turn the to over
